Liquid chromatography-tandem mass spectrometry outperforms fluorescence polarization immunoassay in monitoring everolimus therapy in renal transplantation

Therapeutic Drug Monitoring

Volumn 32, Issue 4, 2010, Pages 413-419

  Moes, Dirk Jan A R ^a   Press, Rogier R ^a   De Fijter, Johan W ^a   Guchelaar, Henk Jan ^a   Den Hartigh, Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

everolimus; FPIA; LC MS MS; method comparison; renal transplantation; therapeutic drug monitoring

Indexed keywords

EVEROLIMUS; PREDNISOLONE; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GRAFT RECIPIENT; HUMAN; INTERMETHOD COMPARISON; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIQUID CHROMATOGRAPHY; MALE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; ANALOGS AND DERIVATIVES; BLOOD; COMPARATIVE STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; QUALITY CONTROL; REPRODUCIBILITY;

ADULT; AGED; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; SIROLIMUS; TANDEM MASS SPECTROMETRY;

EID: 77955174746     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181e5c656     Document Type: Article

References (26)

1. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43:83-95.
2. Kovarik JM, Kahan BD, Kaplan B, et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther. 2001;69:48-56.
3. Baldelli S, Crippa A, Gabrieli R, et al. Comparison of the Innofluor Certican assay with HPLC-UV for the determination of everolimus concentrations in heart transplantation. Clin Biochem. 2006;39:1152-1159.
4. Dailly E, Deslandes G, Hourmant M, et al. Comparison between a liquid chromatography-tandem mass spectrometry assay and a fluorescent polarization immunoassay to measure whole blood everolimus concentration in heart and renal transplantations. J Clin Lab Anal. 2008;22:282-285.
5. Koster RA, Dijkers EC, Uges DR. Robust, high-throughput LC-MS/MS method for therapeutic drug monitoring of cyclosporine, tacrolimus, everolimus, and sirolimus in whole blood. Ther Drug Monit. 2009;31: 116-125.
6. Yang Z, Wang S. Recent development in application of high performance liquid chromatography-tandem mass spectrometry in therapeutic drug monitoring of immunosuppressants. J Immunol Methods. 2008;336: 98-103.
7. Holt DW. Everolimus International Proficiency Testing Scheme. London: The Analytical Unit St George's University of London; 2009.
8. Bemelman FJ, de Maar EF, Press RR, et al. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. Transplantation. 2009;88:421-428.
9. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation-a revisit with a decade of progress. Pharm Res. 2000;17:1551-1557.
10. Seradyn Innofluor Certican Assay System Chart. Indianapolis, IN: Seradyn Inc. 2005.
11. Innofluor Certican Calibrator Product Insert. Indianapolis, IN: Seradyn Inc. 2005.
12. Seradyn Innofluor Certican Control Product Insert. Indianapolis, IN: Seradyn Inc. 2005.
13. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1: 307-310.
14. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999;8:135-160.
15. Dewitte K, Fierens C, Stockl D, et al. Application of the Bland-Altman plot for interpretation of method-comparison studies: a critical investigation of its practice. Clin Chem. 2002;48:799-801.
16. Altman DG, Bland JM. Commentary on quantifying agreement between two methods of measurement. Clin Chem. 2002;48:801-802.
17. Khoschsorur G, Fruehwirth F, Zelzer S, et al. Comparison of fluorescent polarization immunoassay (FPIA) versus HPLC to measure everolimus blood concentrations in clinical transplantation. Clin Chim Acta. 2007; 380:217-221.
18. Salm P, Warnholtz C, Boyd J, et al. Evaluation of a fluorescent polarization immunoassay for whole blood everolimus determination using samples from renal transplant recipients. Clin Biochem. 2006;39:732-738.
19. Kovarik JM, Kalbag J, Figueiredo J, et al. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. J Clin Pharmacol. 2002;42: 95-99.
20. Hoogtanders K, van der HJ, Stolk LM, et al. Internal standard selection for the high-performance liquid chromatography tandem mass spectrometry assay of everolimus in blood. Ther Drug Monit. 2007;29:673-674.
21. Kirchner GI, Winkler M, Mueller L, et al. Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. Br J Clin Pharmacol. 2000; 50:449-454.
22. Schutz E, Streit F, Dias V, et al. CsA immunoassays in comparison to LC-MS/MS, is there a difference between trough (C0) and C2 levels? Ther Drug Monit. 2001;23:471.
23. Johnston A, Chusney G, Schutz E, et al. Monitoring cyclosporin in blood: between-assay differences at trough and 2 hours post-dose (C2). Ther Drug Monit. 2003;25:167-173.
24. Strom T, Haschke M, Boyd J, et al. Crossreactivity of isolated everolimus metabolites with the Innofluor Certican immunoassay for therapeutic drug monitoring of everolimus. Ther Drug Monit. 2007;29:743-749.
25. Strom T, Haschke M, Zhang YL, et al. Identification of everolimus metabolite patterns in trough blood samples of kidney transplant patients. Ther Drug Monit. 2007;29:592-599.
26. Certican® SPC. Summary of product characteristics. Basel, Switzerland: Novartis Pharma AG. 2004.